

Selina M Luger

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8791296/selina-m-luger-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

98
papers

4,615
citations

24
h-index

67
g-index

101
ext. papers

5,541
ext. citations

5.2
avg, IF

4.9
L-index

#	Paper	IF	Citations
98	Letermovir vs. high-dose valacyclovir for cytomegalovirus prophylaxis following haploidentical or mismatched unrelated donor allogeneic hematopoietic cell transplantation receiving post-transplant cyclophosphamide.. <i>Leukemia and Lymphoma</i> , 2022 , 1-9	1.9	0
97	Day 4 vs. day 12 G-CSF administration following reduced intensity peripheral blood allogeneic stem cell transplant.. <i>Journal of Oncology Pharmacy Practice</i> , 2022 , 10781552221080710	1.7	
96	Venetoclax in combination with hypomethylating agents or low dose cytarabine for relapsed and refractory acute myeloid leukemia.. <i>Leukemia and Lymphoma</i> , 2022 , 1-6	1.9	0
95	Patients with AML Who Achieve Long Term Complete Remission Do Not Have a Normal Life Expectancy When Compared to the General Population. Analysis of 3,012 Patients Enrolled on 9 Consecutive ECOG-ACRIN Trials. <i>Blood</i> , 2021 , 138, 690-690	2.2	
94	Incidence and Predictors of Sars-Cov-2 Antibody Responses Following COVID-19 Vaccination in Allogeneic Stem Cell Transplant Recipients. <i>Blood</i> , 2021 , 138, 2888-2888	2.2	0
93	Real World Survival Outcomes of CPX-351 Versus Venetoclax and Azacitadine for Initial Therapy in Adult Acute Myeloid Leukemia. <i>Blood</i> , 2021 , 138, 795-795	2.2	2
92	Tipifarnib as maintenance therapy did not improve disease-free survival in patients with acute myelogenous leukemia at high risk of relapse: Results of the phase III randomized E2902 trial. <i>Leukemia Research</i> , 2021 , 111, 106736	2.7	0
91	Superior survival with pediatric-style chemotherapy compared to myeloablative allogeneic hematopoietic cell transplantation in older adolescents and young adults with Ph-negative acute lymphoblastic leukemia in first complete remission: analysis from CALGB 10403 and the CIBMTR. <i>Leukemia</i> , 2021 , 35, 2076-2085	10.7	10
90	Consolidation Therapy for Acute Myeloid Leukemia: Defining a Benchmark. <i>Journal of Clinical Oncology</i> , 2021 , 39, 870-875	2.2	1
89	Posttraumatic stress disorder symptoms in patients with acute myeloid leukemia. <i>Cancer</i> , 2021 , 127, 2500-2506	6.4	0
88	Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1001-1009	2.2	8
87	Leucovorin Rescue After Methotrexate Graft-Versus-Host Disease Prophylaxis Shortens the Duration of Mucositis, Time to Neutrophil Engraftment, and Hospital Length of Stay. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 431.e1-431.e8		1
86	Characterization of Pericarditis following Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021 , 27, 934.e1-934.e6		1
85	Comparison of CALGB 10403 (Alliance) and COG AALL0232 toxicity results in young adults with acute lymphoblastic leukemia. <i>Blood Advances</i> , 2021 , 5, 504-512	7.8	9
84	Dose intensity for induction in acute myeloid leukemia: what, when, and for whom?. <i>Haematologica</i> , 2021 , 106, 2544-2554	6.6	1
83	Results of a randomized phase 3 study of oral sapacitabine in elderly patients with newly diagnosed acute myeloid leukemia (SEAMLESS). <i>Cancer</i> , 2021 , 127, 4421-4431	6.4	1
82	Interpretative differences of combined cytogenetic and molecular profiling highlights differences between MRC and ELN classifications of AML. <i>Cancer Genetics</i> , 2021 , 256-257, 68-76	2.3	0

81	Acute Lymphoblastic Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021 , 19, 1079-1109	7.3	8
80	CNS involvement in AML at diagnosis is rare and does not affect response or survival: data from 11 ECOG-ACRIN trials. <i>Blood Advances</i> , 2021 , 5, 4560-4568	7.8	3
79	Rapid fluorescence in situ hybridisation optimises induction therapy for acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2020 , 191, 935-938	4.5	2
78	Gender differences in question-asking at the 2019 American Society of Hematology Annual Meeting. <i>Blood Advances</i> , 2020 , 4, 5473-5479	7.8	3
77	Venous thromboembolism following pegaspargase in adults receiving antithrombin supplementation. <i>Leukemia and Lymphoma</i> , 2020 , 61, 2200-2207	1.9	4
76	Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. <i>Leukemia</i> , 2020 , 34, 3149-3160	10.7	19
75	Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy. <i>Leukemia and Lymphoma</i> , 2020 , 61, 1220-1225	1.9	8
74	Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey. <i>Leukemia and Lymphoma</i> , 2020 , 61, 1455-1464	1.9	2
73	Risk of invasive fungal infections in patients with high-risk MDS and AML receiving hypomethylating agents. <i>American Journal of Hematology</i> , 2020 , 95, 792-798	7.1	7
72	Post-Traumatic Stress Disorder (PTSD) Symptoms in Patients with Acute Myeloid Leukemia (AML). <i>Blood</i> , 2020 , 136, 44-45	2.2	1
71	Durable Remissions and Increased Overall Survival in AML Patients Deemed Unfit for Standard Intensive Chemotherapy Achieved with High-Dose BST-236 (Aspacytarabine) Induction and Consolidation. <i>Blood</i> , 2020 , 136, 9-10	2.2	
70	Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2020 , 38, 415-422	2.2	80
69	Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902. <i>Transfusion</i> , 2020 , 60, 1867-1872	2.9	
68	Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. <i>Lancet Haematology</i> , 2020 , 7, e601-e612	14.6	41
67	The relationship between clinical trial accrual volume and outcomes in acute myeloid leukemia: A SWOG/ECOG-ACRIN study (S0106 and E1900). <i>Leukemia Research</i> , 2019 , 78, 29-33	2.7	1
66	Longitudinal targeted next-generation sequencing in a patient with acute myeloid leukaemia. <i>British Journal of Haematology</i> , 2019 , 186, 801	4.5	
65	Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia. <i>Cancer Discovery</i> , 2019 , 9, 1050-1063	24.4	148
64	Relapsed T Cell ALL: Current Approaches and New Directions. <i>Current Hematologic Malignancy Reports</i> , 2019 , 14, 83-93	4.4	31

63	Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract. <i>Bone Marrow Transplantation</i> , 2019 , 54, 212-217	4.4	21
62	Acute myeloid leukemia: How to treat the fit patient over age 75?. <i>Best Practice and Research in Clinical Haematology</i> , 2019 , 32, 101105	4.2	2
61	Superior Survival with Post-Remission Pediatric-Inspired Chemotherapy Compared to Myeloablative Allogeneic Hematopoietic Cell Transplantation in Adolescents and Young Adults with Ph-Negative Acute Lymphoblastic Leukemia in First Complete Remission: Comparison of CALGB 10403 to Patients Reported to the CIBMTR. <i>Blood</i> , 2019 , 134, 261-261	2.2	5
60	Two-dimensional speckle-tracking strain detects subclinical cardiotoxicity in older patients treated for acute myeloid leukemia. <i>Echocardiography</i> , 2019 , 36, 2033-2040	1.5	4
59	Symptomatic Heart Failure in Acute Leukemia Patients Treated With Anthracyclines. <i>JACC: CardioOncology</i> , 2019 , 1, 208-217	3.8	9
58	Maintenance therapy in acute myeloid leukemia: What is the future?. <i>Seminars in Hematology</i> , 2019 , 56, 102-109	4	8
57	A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. <i>Blood</i> , 2019 , 133, 1548-1559	2.2	178
56	A randomized trial of three novel regimens for recurrent acute myeloid leukemia demonstrates the continuing challenge of treating this difficult disease. <i>American Journal of Hematology</i> , 2019 , 94, 111-117 ¹	7.1	19
55	Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial. <i>Biology of Blood and Marrow Transplantation</i> , 2019 , 25, 515-521	4.7	16
54	Oral Vancomycin Prophylaxis Is Highly Effective in Preventing Clostridium difficile Infection in Allogeneic Hematopoietic Cell Transplant Recipients. <i>Clinical Infectious Diseases</i> , 2019 , 68, 2003-2009	11.6	39
53	Sirolimus enhances remission induction in patients with high risk acute myeloid leukemia and mTORC1 target inhibition. <i>Investigational New Drugs</i> , 2018 , 36, 657-666	4.3	8
52	Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Review. <i>JAMA Oncology</i> , 2018 , 4, 725-734	13.4	64
51	Wide Variation in Use and Interpretation of Gene Mutation Profiling Panels Among Health Care Providers of Patients with Myelodysplastic Syndromes (MDS): Results of a Large Web-Based Survey. <i>Blood</i> , 2018 , 132, 1825-1825	2.2	2
50	Higher Donor Apheresis Blood Volumes Are Associated with Reduced Relapse Risk and Improved Survival in Reduced-Intensity Allogeneic Transplantations with Unrelated Donors. <i>Biology of Blood and Marrow Transplantation</i> , 2018 , 24, 1203-1208	4.7	1
49	Minimal Residual Disease in Acute Myeloid Leukemia. <i>Current Treatment Options in Oncology</i> , 2017 , 18, 1	5.4	14
48	High Frequency and Poor Outcome of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Adults. <i>Journal of Clinical Oncology</i> , 2017 , 35, 394-401	2.2	227
47	How can one optimize induction therapy in AML?. <i>Best Practice and Research in Clinical Haematology</i> , 2017 , 30, 301-305	4.2	14
46	Time to unrelated donor leukocyte infusion is longer, but incidence of GVHD and overall survival are similar for recipients of unrelated DLI compared to matched sibling DLI. <i>American Journal of Hematology</i> , 2016 , 91, 426-9	7.1	1

45	Distinct evolution and dynamics of epigenetic and genetic heterogeneity in acute myeloid leukemia. <i>Nature Medicine</i> , 2016 , 22, 792-9	50.5	217
44	Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 248-257	4.7	27
43	Nelarabine, cyclophosphamide and etoposide for adults with relapsed T-cell acute lymphoblastic leukaemia and lymphoma. <i>British Journal of Haematology</i> , 2016 , 174, 332-4	4.5	11
42	A clinical measure of DNA methylation predicts outcome in de novo acute myeloid leukemia. <i>JCI Insight</i> , 2016 , 1,	9.9	14
41	Acute promyelocytic leukemia presenting as a paraspinal mass. <i>Journal of Community and Supportive Oncology</i> , 2016 , 14, 126-9		6
40	A Modified Integrated Genetic Model for Risk Prediction in Younger Patients with Acute Myeloid Leukemia. <i>PLoS ONE</i> , 2016 , 11, e0153016	3.7	9
39	Infusion of CD3/CD28 costimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftment. <i>American Journal of Hematology</i> , 2016 , 91, 453-60	7.1	6
38	Unrelated donors are associated with improved relapse-free survival compared to related donors in patients with myelodysplastic syndrome undergoing reduced intensity allogeneic stem cell transplantation. <i>American Journal of Hematology</i> , 2016 , 91, 883-7	7.1	2
37	Benefit of high-dose daunorubicin in AML induction extends across cytogenetic and molecular groups. <i>Blood</i> , 2016 , 127, 1551-8	2.2	81
36	Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008. <i>Journal of Clinical Oncology</i> , 2016 , 34, 3544-3553	2.2	65
35	Clinical Utility of Next-Generation Sequencing for Oncogenic Mutations in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016 , 22, 1961-1967	4.7	25
34	Efficacy of Retinoids in IKZF1-Mutated BCR-ABL1 Acute Lymphoblastic Leukemia. <i>Cancer Cell</i> , 2015 , 28, 343-56	24.3	114
33	A genome-wide association study of susceptibility to acute lymphoblastic leukemia in adolescents and young adults. <i>Blood</i> , 2015 , 125, 680-6	2.2	84
32	Combined B12 and folate deficiency presenting as an aggressive hematologic malignancy. <i>American Journal of Hematology</i> , 2015 , 90, 964-5	7.1	3
31	How I treat adults with relapsed or refractory Philadelphia chromosome-negative acute lymphoblastic leukemia. <i>Blood</i> , 2015 , 126, 589-96	2.2	48
30	High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning. <i>Journal of Clinical Oncology</i> , 2015 , 33, 2392-8	2.2	38
29	Patterns of Venous Thromboembolism Prophylaxis During Treatment of Acute Leukemia: Results of a North American Web-Based Survey. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015 , 15, 766-770	2	11
28	DNMT3A Mutational Status Affects the Results of Dose-Escalated Induction Therapy in Acute Myelogenous Leukemia. <i>Clinical Cancer Research</i> , 2015 , 21, 1614-20	12.9	40

27	A Clinical Measure of DNA Methylation Predicts Outcome in De Novo AML. <i>Blood</i> , 2015 , 126, 2591-2591	2.2	
26	Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2014 , 20, 1758-66	4.7	39
25	Phase I study of Debio1143 (AT406) in combination with daunorubicin (D) and cytarabine (C) in patients with poor-risk acute myeloid leukemia (AML).. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7029-7029	2.2	2
24	Next-generation sequencing to identify mutations that may predict outcome after allogeneic stem cell transplantation for AML.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7043-7043	2.2	1
23	Predicting prognosis in patients with acute myeloid leukemia: The role of next-generation sequencing and mutational profiling.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 7068-7068	2.2	
22	Delays in Start of Intensification Therapy Are Common for Adults with Acute Lymphoblastic Leukemia, and Are Associated with Decreased Survival in Patients Who Undergo Allogeneic Stem Cell Transplant (SCT). <i>Blood</i> , 2014 , 124, 208-208	2.2	
21	Time from Relapse to Donor Leukocyte Infusion in Allogeneic Stem Cell Transplantation Patients Is Longer for Recipients of Unrelated DLI Compared to Matched Sibling DLI, with Similar Incidence of Graft Versus Host Disease (GVHD) and Survival. <i>Blood</i> , 2014 , 124, 3946-3946	2.2	
20	A phase II study of mocetinostat, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in combination with 5-azacitidine in patients with myelodysplastic syndrome (MDS).. <i>Journal of Clinical Oncology</i> , 2013 , 31, 7116-7116	2.2	5
19	Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. <i>New England Journal of Medicine</i> , 2012 , 366, 1079-89	59.2	1378
18	R115777(tipifarnib) Improves Early Survival when Used As Maintenance Therapy for Elderly or Relapsed/Refractory Patients with Acute Myelogenous Leukemia in Remission. <i>Blood</i> , 2012 , 120, 676-676	2.2	1
17	A randomized phase II study of sapacitabine in MDS refractory to hypomethylating agents.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 6520-6520	2.2	
16	Outcome of acute myeloid leukemia in patients with a history of autoimmune disease.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 6579-6579	2.2	
15	A Feasibility Study of Rapamycin with Hyper-CVAD Chemotherapy in Adults with Acute Lymphoblastic Leukemia (ALL) and Other Aggressive Lymphoid Malignancies and Evaluation of mTOR Signaling Using Phosphoflow. <i>Blood</i> , 2011 , 118, 4245-4245	2.2	
14	Treating the elderly patient with acute myelogenous leukemia. <i>Hematology American Society of Hematology Education Program</i> , 2010 , 2010, 62-9	3.1	33
13	Single-Cell Pharmacodynamic Monitoring of S6 Ribosomal Protein in AML Blasts During a Clinical Trial Combining the mTOR Inhibitor Sirolimus with Mitoxantrone, Etoposide, and Cytarabine Chemotherapy.. <i>Blood</i> , 2009 , 114, 413-413	2.2	
12	In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients. <i>Journal of Clinical Oncology</i> , 2009 , 27, 1827-33	2.2	590
11	Initial Safety, Pharmacokinetic and Pharmacodynamic Data from a Phase I Clinical Trial of Systemic C-MYB Antisense Oligodeoxynucleotide in Subjects with Refractory Hematologic Malignancies. <i>Blood</i> , 2008 , 112, 4033-4033	2.2	
10	Phase I/II Study of MGCD0103, an Oral Isotype-Selective Histone Deacetylase (HDAC) Inhibitor, in Combination with 5-Azacitidine in Higher-Risk Myelodysplastic Syndrome (MDS) and Acute Myelogenous Leukemia (AML).. <i>Blood</i> , 2007 , 110, 444-444	2.2	13

9	Does Imatinib Change the Outcome in Philadelphia Chromosome Positive Acute Lymphoblastic Leukaemia in Adults? Data from the UKALLXII/ECOG2993 Study.. <i>Blood</i> , 2007 , 110, 8-8	2.2	18
8	Systemic Inflammatory Response Syndrome (SIRS) as Predictor of Severe Sepsis (SS) in Hospitalized Patients (pts) with Hematologic Malignancies.. <i>Blood</i> , 2007 , 110, 633-633	2.2	1
7	Timing between Rituximab and 90Y-Ibritumomab Tiuxetan in Pts with Non-Hodgkin's Lymphoma Does Not Affect Clinical Outcomes.. <i>Blood</i> , 2006 , 108, 4735-4735	2.2	
6	A Predictive Model for Cytogenetic Risk Group in Elderly AML: The Penn Cytogenetic Surrogate Score (PCSS).. <i>Blood</i> , 2006 , 108, 4446-4446	2.2	
5	Expression of tumor-suppressor genes interferon regulatory factor 1 and death-associated protein kinase in primitive acute myelogenous leukemia cells. <i>Blood</i> , 2001 , 97, 2177-9	2.2	47
4	Nuclear factor-kappaB is constitutively activated in primitive human acute myelogenous leukemia cells. <i>Blood</i> , 2001 , 98, 2301-7	2.2	631
3	Soluble interleukin-2 receptor concentration as a biochemical indicator for acute graft-versus-host disease after allogeneic bone marrow transplantation. <i>Journal of Hematotherapy and Stem Cell Research</i> , 2000 , 9, 393-400		19
2	Stem cell transplantation for metastatic breast cancer: analysis of tumor contamination. <i>Medical Oncology and Tumor Pharmacotherapy</i> , 1999 , 16, 279-88		10
1	Pentosan polysulfate for the treatment of hemorrhagic cystitis after allogeneic hematopoietic cell transplant. <i>Journal of Oncology Pharmacy Practice</i> , 107815522211052	1.7	